Trajectories of subjective cognitive decline, and the risk of mild cognitive impairment and dementia
- PMID: 33109275
- PMCID: PMC7592368
- DOI: 10.1186/s13195-020-00699-y
Trajectories of subjective cognitive decline, and the risk of mild cognitive impairment and dementia
Abstract
Background: In cognitively normal individuals, subjective cognitive decline (SCD) has been reported to predict MCI and dementia (MCI/dementia). However, prior studies mostly captured SCD at single time-points without considering the longitudinal course of SCD. This study examined whether the trajectories of SCD provide any added information-beyond one-time assessments of SCD-on the risk of MCI/dementia.
Methods: This cohort study included 5661 participants from the Alzheimer's Disease Centers across the USA, who were ≥ 50 years and had normal cognition in the first-four annual visits (year 1 to year 4). The participants were evaluated for SCD in the first-four annual visits (year 1 to year 4), and followed-up almost annually (year 4 up to year 14) for incident MCI/dementia. SCD trajectories (as identified from latent-class-growth-curve-analysis) were included in Cox regression to estimate their risks of MCI/dementia, with analyses further stratified by age (< 75 years versus ≥ 75 years; based on median-split).
Results: Compared to those without SCD (in the first-four annual visits), Intermittent SCD (i.e., reported in 1-2 of the first-four annual visits) predicted a higher risk (HR 1.4) and Persistent SCD (i.e., reported in 3-4 of the first-four annual visits) predicted the highest risk (HR 2.2), with the results remaining significant even after adjusting for baseline SCD. Age-stratified analysis revealed that the risk associated with Intermittent SCD was only present in older individuals, while risk related to Persistent SCD was consistently present across the younger and older age groups. Age compounded the effects of the trajectories, whereby older individuals with Persistent SCD had > 75% probability of developing MCI/dementia by 10 years, in contrast to < 25% probability by 10 years in younger individuals with No SCD.
Conclusions: The findings demonstrate the utility of SCD trajectories-especially when used in combination with age strata-in identifying high-risk populations for preventive interventions and trials. They also suggest a potential modification in the current SCD criteria, with the inclusion of "persistent SCD over several years" as a feature of SCD plus.
Keywords: Cohort study; Cox regression; Dementia; Mild cognitive impairment; Subjective cognitive complaints; Trajectory; Utility.
Conflict of interest statement
The author declares no competing interests.
Figures



Similar articles
-
Subjective cognitive decline, anxiety symptoms, and the risk of mild cognitive impairment and dementia.Alzheimers Res Ther. 2020 Sep 11;12(1):107. doi: 10.1186/s13195-020-00673-8. Alzheimers Res Ther. 2020. PMID: 32917264 Free PMC article.
-
Health-related quality of life in subjective cognitive decline and mild cognitive impairment: a longitudinal cohort analysis.Alzheimers Res Ther. 2023 Nov 15;15(1):200. doi: 10.1186/s13195-023-01344-0. Alzheimers Res Ther. 2023. PMID: 37968734 Free PMC article.
-
Depression, subjective cognitive decline, and the risk of neurocognitive disorders.Alzheimers Res Ther. 2019 Aug 9;11(1):70. doi: 10.1186/s13195-019-0527-7. Alzheimers Res Ther. 2019. PMID: 31399132 Free PMC article.
-
Subjective Cognitive Decline: Level of Risk for Future Dementia and Mild Cognitive Impairment, a Meta-Analysis of Longitudinal Studies.Neuropsychol Rev. 2022 Dec;32(4):703-735. doi: 10.1007/s11065-021-09522-3. Epub 2021 Nov 8. Neuropsychol Rev. 2022. PMID: 34748154 Review.
-
A Systematic Review of Subjective Cognitive Characteristics Predictive of Longitudinal Outcomes in Older Adults.Gerontologist. 2023 May 9;63(4):700-716. doi: 10.1093/geront/gnac109. Gerontologist. 2023. PMID: 35908232
Cited by
-
Cost-benefit and discriminant validity of a stepwise dementia case-finding approach in an Asian older adult community.Gen Psychiatr. 2023 Oct 30;36(5):e101049. doi: 10.1136/gpsych-2023-101049. eCollection 2023. Gen Psychiatr. 2023. PMID: 37920408 Free PMC article.
-
Lower odor identification in subjective cognitive decline: a meta-analysis.Alzheimers Dement (Amst). 2025 Aug 17;17(3):e70168. doi: 10.1002/dad2.70168. eCollection 2025 Jul-Sep. Alzheimers Dement (Amst). 2025. PMID: 40827140 Free PMC article.
-
Circulating Neurofilament Light Predicts Cognitive Decline in Patients With Post-stroke Subjective Cognitive Impairment.Front Aging Neurosci. 2021 May 17;13:665981. doi: 10.3389/fnagi.2021.665981. eCollection 2021. Front Aging Neurosci. 2021. PMID: 34079450 Free PMC article.
-
Population measures of subjective cognitive decline: A means of advancing public health policy to address cognitive health.Alzheimers Dement (N Y). 2021 Mar 1;7(1):e12142. doi: 10.1002/trc2.12142. eCollection 2021. Alzheimers Dement (N Y). 2021. PMID: 33681450 Free PMC article.
-
A multidimensional model of memory complaints in older individuals and the associated hub regions.Front Aging Neurosci. 2023 Dec 21;15:1324309. doi: 10.3389/fnagi.2023.1324309. eCollection 2023. Front Aging Neurosci. 2023. PMID: 38187362 Free PMC article.
References
-
- Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chetelat G, Dubois B, Dufouil C, Ellis KA, van der Flier WM, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement. 2014;10(6):844–852. doi: 10.1016/j.jalz.2014.01.001. - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
- P50 AG005142/AG/NIA NIH HHS/United States
- P50 AG016573/AG/NIA NIH HHS/United States
- P50 AG047266/AG/NIA NIH HHS/United States
- P30 AG010161/AG/NIA NIH HHS/United States
- P50 AG025688/AG/NIA NIH HHS/United States
- P50 AG005133/AG/NIA NIH HHS/United States
- P50 AG005138/AG/NIA NIH HHS/United States
- P50 AG047366/AG/NIA NIH HHS/United States
- P30 AG010129/AG/NIA NIH HHS/United States
- P30 AG019610/AG/NIA NIH HHS/United States
- P30 AG028383/AG/NIA NIH HHS/United States
- P50 AG033514/AG/NIA NIH HHS/United States
- P30 AG013854/AG/NIA NIH HHS/United States
- P30 AG053760/AG/NIA NIH HHS/United States
- P30 AG010124/AG/NIA NIH HHS/United States
- P50 AG023501/AG/NIA NIH HHS/United States
- P50 AG005131/AG/NIA NIH HHS/United States
- P30 AG010133/AG/NIA NIH HHS/United States
- P50 AG016574/AG/NIA NIH HHS/United States
- P50 AG005146/AG/NIA NIH HHS/United States
- P30 AG035982/AG/NIA NIH HHS/United States
- P50 AG008702/AG/NIA NIH HHS/United States
- U01 AG016976/AG/NIA NIH HHS/United States
- P30 AG008051/AG/NIA NIH HHS/United States
- P50 AG005681/AG/NIA NIH HHS/United States
- P30 AG013846/AG/NIA NIH HHS/United States
- P50 AG047270/AG/NIA NIH HHS/United States
- P50 AG005136/AG/NIA NIH HHS/United States
- P30 AG049638/AG/NIA NIH HHS/United States
- P30 AG012300/AG/NIA NIH HHS/United States
- P50 AG005134/AG/NIA NIH HHS/United States
- P30 AG008017/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical